Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants

被引:0
|
作者
MAO Qun-ying
机构
关键词
D O I
暂无
中图分类号
R686 [筋腱、韧带、滑囊疾病及损伤];
学科分类号
1002 ; 100210 ;
摘要
Background Enterovirus 71 (EV71) and coxsackievirus A16 (Cox A16) are major causative agents for hand, foot andmouth disease (HFMD). Studies indicate that the frequent HFMD outbreaks result in a few hundreds children’s death inChina in recent years. The vaccine and other research for HFMD need to be developed urgently. The aims of our studywere: to explore dynamic development of mother-source neutralizing antibodies against EV71 and Cox A16 in infantsfrom Jiangsu Province, China, and to provide the fundamental data for further establishing of correspondingimmunization course.Methods Peripheral blood samples were collected from 133 of parturient women once immediately before delivery andtheir infants at two and seven months of age. Method of micro-dose cytopathogenic effect was used to measureneutralizing antibodies against EV71 and Cox A16, respectively.Results Seropositive rates of anti-EV71 and anti-Cox A16 in prenatal women were 79.7% (106/133) and 92.5%(123/133), respectively; geometric mean titers (GMTs) were 29.0 and 61.9; 75.9% (101/133) prenatal women were bothpositive in anti-EV71 and anti-Cox A16; seropositive rates of anti-EV71 and anti-Cox A16 were 25.6% (34/133) and38.3% (51/133) in infants at two months of age; GMTs were 12.3 and 18.0, respectively. GMTs of anti-EV71 weresignificantly higher for infants at seven months (82.6) compared with that at two months (P <0.05), showing infants hadinapparently infected by EV71 during two to seven months. Although only one offspring (0.75%) at seven months wasfound having anti-Cox A16 transfered from maternal, this observation suggested no maternal antibody may remain ininfants at seven months.Conclusions The prevalence of EV71 and Cox A16 were relatively high in Jiangsu Province. Bivalent vaccine againstboth EV71 and Cox A16 should be developed, and the ideal time point for prime immunization for infants is around 2-5months of age.
引用
下载
收藏
页码:1679 / 1684
相关论文
共 50 条
  • [21] Genetic characteristic of Enterovirus 71 and Coxsackievirus A16 complete genome isolated in Beijing, 2008
    Yao, X.
    Mao, Q. Y.
    Zhou, C.
    He, P.
    Zhu, X. F.
    Zhang, W.
    Lu, F. M.
    Liang, Z. L.
    Li, F. X.
    Wang, J. Z.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : S3 - S3
  • [22] Bioinformatics-based prediction of conformational epitopes for Enterovirus A71 and Coxsackievirus A16
    Wang, Liping
    Zhu, Miao
    Fang, Yulu
    Rong, Hao
    Gao, Liuying
    Liao, Qi
    Zhang, Lina
    Dong, Changzheng
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [23] Systematic Identification and Bioinformatic Analysis of MicroRNAs in Response to Infections of Coxsackievirus A16 and Enterovirus 71
    Zhu, Zheng
    Qi, Yuhua
    Fan, Huan
    Cui, Lunbiao
    Shi, Zhiyang
    BIOMED RESEARCH INTERNATIONAL, 2016, 2016
  • [24] Transcriptome analysis following enterovirus 71 and coxsackievirus A16 infection in respiratory epithelial cells
    Song, Jie
    Hu, Yajie
    Li, Weiyu
    Li, Hui
    Zheng, Huiwen
    Chen, Yanli
    Dong, Shaozhong
    Liu, Longding
    ARCHIVES OF VIROLOGY, 2020, 165 (12) : 2817 - 2828
  • [25] Immunity to avirulent enterovirus 71 and coxsackie a16 virus protects against enterovirus 71 infection in mice
    Wu, Te-Chia
    Wang, Ya-Fang
    Lee, Yi-Ping
    Wang, Jen-Ren
    Liu, Ching-Chuan
    Wang, Shih-Min
    Lei, Huan-Yao
    Su, Ih-Jen
    Yu, Chun-Keung
    JOURNAL OF VIROLOGY, 2007, 81 (19) : 10310 - 10315
  • [26] A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice
    Yang, Lisheng
    Liu, Yajing
    Li, Shuxuan
    Zhao, Huan
    Lin, Qiaona
    Yu, Hai
    Huang, Xiumin
    Zheng, Qingbing
    Cheng, Tong
    Xia, Ningshao
    VACCINE, 2016, 34 (48) : 5938 - 5945
  • [27] A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses
    Cai, Yicun
    Ku, Zhiqiang
    Liu, Qingwei
    Leng, Qibin
    Huang, Zhong
    VACCINE, 2014, 32 (21) : 2406 - 2412
  • [28] Evaluation of human enterovirus 71 and coxsackievirus A16 specific immunoglobulin M antibodies for diagnosis of hand-foot-and-mouth disease
    Nan Yu
    Min Guo
    Si-Jie He
    Yu-Xian Pan
    Xin-Xin Chen
    Xi-Xia Ding
    Wei Hao
    Ya-Di Wang
    Sheng-Xiang Ge
    Ning-Shao Xia
    Xiao-Yan Che
    Virology Journal, 9
  • [29] The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals
    Mao, Qunying
    Wang, Yiping
    Shao, Jie
    Ying, Zhifang
    Gao, Fan
    Yao, Xin
    Li, Changgui
    Ye, Qiang
    Xu, Miao
    Li, Rongcheng
    Zhu, Fengcai
    Liang, Zhenglun
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (11) : 2723 - 2733
  • [30] Detection of human enterovirus 71 and coxsackievirus A16 in children with hand, foot and mouth disease in China
    Chen, Ling
    Mou, Xiaozhou
    Zhang, Qiong
    Li, Yifei
    Lin, Jian
    Liu, Fanlong
    Yuan, Li
    Tang, Yiming
    Xiang, Charlie
    MOLECULAR MEDICINE REPORTS, 2012, 5 (04) : 1001 - 1004